background image

Entering a new age in cancer drug development

Cancer drug development has accelerated over the last 20 years, yet children with cancer continue to be left behind. Children with cancer in the US first gain access to cutting-edge investigational treatments an average of 6.5 years later than adults. As a result, only 10 new drugs for pediatric cancer have been FDA approved over the last 30 years. This disparity in access and innovation is driven by historical misperceptions about safety, regulatory hurdles, complexity of impending pediatric clinical trials, and market sizes.

Day One takes a different approach, encompassing patients of all ages

Inspired by a call to action from the pediatric oncology community, Day One listens to, and acts in service of the needs of patients, their families, and their treating oncologists. Recognizing that many new treatments can benefit both children and adults with cancer based on a tumor’s underlying biology, Day One prioritizes programs that can be rapidly brought to market for both younger and older patients.

We invite pediatric oncology investigators and the parent advocacy community to partner with us to identify the most relevant and valuable new treatments. We will relentlessly follow the data and rigorously evaluate proposed ideas. Our goal is to license and acquire the most promising products from research institutions as well as biotechnology and pharmaceutical companies.

We bring unsurpassed ingenuity, integrity, experience, and commitment to our partnerships, as we pursue clinical trials in both children and adults. We believe there is a new, better, and faster way to advance novel cancer medicines to improve the lives of patients of all ages.

Our name, Day One, was inspired by the “The Day One Talk.” Keeping the needs of patients and oncologists in mind, we focus our efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. Together we can re-envision cancer drug development and redefine what’s possible in the lives of people with cancer – whatever their age – starting from Day One.

Our mission

Inspired by the urgent needs of children with cancer, Day One creatively and intentionally develops new medicines for people of all ages living with cancer.

Leaders with experience, ingenuity, and integrity

Julie Grant, MPhil, MBA

Julie Grant, MPhil, MBA

Co-founder and
Chief Executive Officer

Julie Grant, MPhil, MBA

Julie Grant, MPhil, MBA

Co-founder and
Chief Executive Officer

Julie Grant, co-founder and CEO of Day One, is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She primarily leads investments and company formation ,efforts in biopharmaceuticals. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new ventures including Nocion, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko, Vineti, and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a BS in Molecular Biophysics and Chemistry from Yale, an MPhil BioScience Enterprise from Cambridge, and MBA from Stanford.

Fun Fact

Julie is a junior sailing and college national sailing champion, who represented the US internationally.

Samuel Blackman, MD, PhD

Samuel Blackman, MD, PhD

Co-founder and Chief Medical Officer

Samuel Blackman, MD, PhD

Samuel Blackman, MD, PhD

Co-founder and Chief Medical Officer

Sam Blackman, co-founder and Chief Medical Officer of Day One, is a physician-scientist trained in pediatric hematology/oncology and neuro-oncology, and has led the early clinical development of more than 10 novel cancer therapeutics. Prior to founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, where he led the advancement of a novel immunotherapeutic towards Phase 1 clinical trials. Prior to Mavupharma, he was Head of Clinical Development at Silverback Therapeutics. Prior to Silverback, Dr. Blackman held roles of increasing responsibility at Juno Therapeutics, Seattle Genetics, Merck, and GlaxoSmithKline. Dr. Blackman was responsible for the pediatric development of dabrafenib, resulting in the first industry-sponsored pediatric oncology “basket trial.” Through roles at CureSearch and ACCELERATE, Dr. Blackman is an active leader in the pediatric oncology drug development community.

Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his MD and PhD degrees from the University of Illinois at Chicago.

Fun Fact

While living in Chicago, Sam supported himself through medical and graduate school as a Spinning™ instructor.

Mike Preigh, PhD

Mike Preigh, PhD

Chief of Technology Operations

Mike Preigh, PhD

Mike Preigh, PhD

Chief of Technology Operations

Mike brings over 25 years of experience in product development and manufacturing to Day One. Prior to joining Day One, he was an independent consultant supporting CMC development for multiple venture backed start-up companies. He spent 10 years at Array BioPharma, where he led a CMC group that successfully filed INDs for 20+ new chemical entities and supported clinical development of multiple marketed drugs including binimetinib and tucatinib. He also spent 12 years at Pfizer in Manufacturing and R&D. He received his PhD in Chemistry from the University of Pittsburgh and his BA Chemistry from Illinois Wesleyan University.

Fun Fact

Mike worked through college as an elementary school playground supervisor, baseball umpire, and waste-water treatment technician among many other jobs.

Sharon Tetlow, MBA

Sharon Tetlow, MBA

Consulting Chief Financial Officer

Sharon Tetlow, MBA

Sharon Tetlow, MBA

Consulting Chief Financial Officer

Sharon Tetlow, consulting CFO of Day One, is the founding partner at Potrero Hill Advisors, LLC, a financial services firm serving biotech companies as they grow from seed to IPO, and into the public space. Sharon and her team have supported more than two dozen biotech companies including CytomX, Allakos, and Principia through financings, audits and several acquisitions. Sharon was previously CFO of a series of both public and private biotech companies. She is on the board of Catalyst Biosciences (CBIO) and Project Open Mind. She earned a BA from the University of Delaware and MBA from Stanford.

Fun Fact

Has belly-crawled beneath huckleberry shrubs to bag Craterellus cornucopioides blooms.

Davy Chiodin, PharmD

Davy Chiodin, PharmD

SVP of Product Development

Davy Chiodin, PharmD

Davy Chiodin, PharmD

SVP of Product Development

Dr. Davy Chiodin brings to Day One nearly 20 years of pharmaceutical industry experience and 15 years of oncology development experience across tumor types and stages of development. Prior to joining Day One, Davy was at Acerta, a member of the AstraZeneca group, where he led the Regulatory Science and Quality Assurance functions through the acalabrutinib global filings and the build of the AZ hematology franchise. Davy spent more than 10 years at Roche/Genentech, assuming roles of increased responsibility in the Regulatory function in both Europe and the US, including 2 years fully dedicated to the pediatric oncology portfolio. He has remained an active contributor to the pediatric oncology community since then.

Davy received his PharmD from the university of Grenoble, France, and a Master in Regulatory Affairs and Pharmacoeconomics from the universities of Lille and Paris, France.

Fun Fact

Davy was born in the Alps and was put on skis nearly at the same time as he learned to walk.

Isagani Cornelio

Isagani Cornelio

VP of Clinical Operations

Isagani Cornelio

Isagani Cornelio

VP of Clinical Operations

Isagani “Izzy” Cornelio brings over 20 years of clinical operations experience to Day One. His experience at Amgen Inc. included Clinical Affairs in the neurology and inflammation therapeutic areas; additionally, he oversaw the Medical Affairs Inflammation peri-approval trials and investigator-sponsored program. Izzy built upon this experience with positions at Kythera Biopharmaceuticals (dermatology) and Exelixis Inc.(solid tumor). He was recently VP Clinical Operations at Rainier Therapeutics (fka BioClin Therapeutics) where he oversaw all aspects of their clinical operations function. Mr. Cornelio received his BS from the University of California, Los Angeles, and conducted post graduate course work at Cornell University.

Fun Fact

Izzy is a frustrated actor, singer, and racecar driver (“Frustrated” = ineffectual in a particular skill, but lacking self-awareness to admit one’s abysmal failure in such).

Michael Cox, PharmD, MHSc, BCOP

Michael Cox, PharmD, MHSc, BCOP

Vice President, Clinical Development

Michael Cox, PharmD, MHSc, BCOP

Michael Cox, PharmD, MHSc, BCOP

Vice President, Clinical Development

Dr. Michael Cox joins Day One Biopharmaceuticals with 15 years of clinical development and medical affairs experience. He has led the clinical development, product launches, and life cycle management of numerous oncology products including selpercatinib, larotrectinib (VITRAKVI®), radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®), cetuximab (ERBITUX®), denosumab (XGEVA®), and darbepoetin alfa (Aranesp®). Dr. Cox has authored papers published in The New England Journal of Medicine, Lancet Oncology, and other prestigious journals. Prior to joining Day One, he was Executive Director, Pediatric Clinical Development at Loxo Oncology, where he led medical affairs and pediatric clinical development. Prior to joining Loxo Oncology, Dr. Cox held global and regional medical affairs positions of increasing responsibility at Bayer Pharmaceuticals, Basel, Switzerland, Merck KGaA, Darmstadt, Germany, and Amgen, Inc., Thousand Oaks, California. He holds a PharmD from Ohio Northern University and an MHSc from Duke University. Dr. Cox completed post-graduate training at Mission Hospitals, the University of Pittsburgh Medical Center, and the National Cancer Institute.

Fun Fact

Michael’s desire to disrupt the norm became evident on his first report card in kindergarten, which included the note “Michael is a great student, however he needs to work on coloring within the lines.”

Eleni Venetsanakos, PhD

Eleni Venetsanakos, PhD

Sr. Director of Translational Sciences

Eleni Venetsanakos, PhD

Eleni Venetsanakos, PhD

Sr. Director of Translational Sciences

Dr. Eleni Venetsanakos is a cancer and translational biologist joining Day One as the Senior Director of Translational Sciences. Before joining Day One, Eleni spent 18 years in industry driving translational work, including biomarker discovery and development, combination strategy and mechanistic insights into drug resistance for novel oncology therapeutics. Eleni spent 13 years at Chiron/Novartis, and more recently, two startups, Principia Biopharma, as the Translational Lead for a clinical stage drug development program and Ideaya Biosciences, where she built and led the In Vivo Pharmacology group. She earned a BSc at University of Tasmania, Australia, a PhD in tumor immunology at Flinders University, Australia, and worked as a postdoctoral scientist at the QEII Medical Center, Perth, Australia, and the UCSF Comprehensive Cancer Center, San Francisco with Dr. Martin McMahon.

Fun Fact

Eleni has seen, and been in awe of, the stunning mirror reflections in Salar de Uyuni, Bolivia.

Cindy Cohen, MBA

Cindy Cohen, MBA

Sr. Director of Program Management

Cindy Cohen, MBA

Cindy Cohen, MBA

Sr. Director of Program Management

Cindy Cohen joins the Day One team from Myovant Sciences, where she was most recently Senior Director of Program & Alliance Management responsible for driving delivery of their Ph3 programs and filing of their first New Drug Application. Cindy brings more than 20 years of industry experience having worked at Genentech/Roche and four biotech startups. Cindy received her MBA from UC Berkeley Haas School of Business and a BS in Biochemistry and Cell Biology from UC San Diego.

Fun Fact

Cindy enjoys exploring the world (on land and sea) with her daughter and husband.

Cydrienne Llamas

Cydrienne Llamas

Senior Manager in Regulatory Science and Operations

Cydrienne Llamas

Cydrienne Llamas

Senior Manager in Regulatory Science and Operations

Cydrienne Llamas joins Day One as Senior Manager in Regulatory Science and Operations. Previously, she worked at Acerta Pharma, a member of the AstraZeneca group, where she led and managed the publishing activities of Calquence for the treatment of CLL or SLL under two FDA pilot programs: Real-Time Oncology Review and Project Orbis. In addition to Regulatory Operations responsibilities, she also generated and implemented an action plan as the main Reg Ops interface between Acerta and AZ and providing creative solutions in a complex filing strategy. Prior to Acerta, Cydrienne spent five years at Gilead in their Regulatory Operations group where she worked on numerous major filings across multiple therapeutics areas while developing and leading cross-functional process improvements. Her passions include cooking, travelling and dancing Hula and Ori Tahiti.

Fun Fact

She has read all the books Harry Potter books and watched all the movies enough times to know the lines by heart.

Maria Pulido

Maria Pulido

Executive Assistant and
Office Manager

Maria Pulido

Maria Pulido

Executive Assistant and
Office Manager

Maria Pulido joins Day One as an experienced accountant and administration manager. Before joining Day One, she worked at Acerta Pharma, a member of the AstraZeneca group, where she supported the VP of Regulatory Science and led training and support for procurement and accounting. Prior to Acerta, Maria worked with a Third Party Administrator for 16 years where she managed the Accounts Payable, Accounts Receivables, Customer Service, and Front Office teams.

Fun Fact

Maria loves to crochet and volunteer her time as a Catechist Teacher.

Board of Directors and Observers

Julie Grant, MBA, MPhil

Director

Julie Grant, MBA, MPhil

Director

Julie Grant, co-founder and CEO of Day One, is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She primarily leads investments and company formation efforts in biopharmaceuticals. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new ventures including Nocion, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko, Vineti and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a BS in Molecular Biophysics and Chemistry from Yale, an MPhil BioScience Enterprise from Cambridge, and MBA from Stanford.

Dan Becker, MD, PhD

Director

Dan Becker, MD, PhD

Director

Dan Becker is a Principal at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group with global strategic investments of $25+ billion. Prior to joining Access, Dan was a Principal at New Leaf Venture Partners, where he played a key role in multiple private and public biopharma investments, and a Principal in the Health Care practice at the Boston Consulting Group, where he led projects across the healthcare sector with an emphasis on biopharma R&D. Dan trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his MD and PhD (Cellular and Molecular Biology) degrees from the University of Michigan, and received his BS in Physiology from the University of Illinois at Urbana-Champaign.

Michael Gladstone

Director

Michael Gladstone

Director

Michael Gladstone is a Principal at Atlas Venture, where he builds new therapeutics companies, primarily in the areas of oncology and immunology.

Michael contributed to launching several Atlas-originated companies, including Padlock Therapeutics (acquired by BMS), Surface Oncology (NASDAQ: SURF), and IFM Therapeutics Inc (acquired by BMS; and its spinout IFM Tre acquired by Novartis). He has served as a board member or observer for IFM Therapeutics LLC, Indalo Therapeutics, Akrevia Therapeutics, AvroBio (NASDAQ: AVRO), Akero (NASDAQ: AKRO), Delinia (acquired by Celgene), and Replimune (NASDAQ: REPL).

Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting and previously, he conducted HIV vaccine research in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center.

Michael serves as an advisor to several organizations, including as member of the Corporate Advisory Committee for National Tay Sachs and Allied Diseases, a national organization focused on funding research, promoting awareness, and supporting families affected by Tay-Sachs and related genetic diseases.

Dan Curran, MD

Observer

Dan Curran, MD

Observer

Dr. Daniel Curran is the Head of the Rare Diseases Therapeutic Area Unit (TAU) at Takeda Pharmaceutical Company Limited. In this role, he leads Takeda’s efforts to unlock innovation and deliver transformative medicines in the areas of rare immunology, rare hematology, lysosomal storage disorders, rare genetic and metabolic diseases, and other disease areas.

Previously, Dr. Curran served as Head of Takeda’s Center for External Innovation (CEI). In this role, he and his team diversified Takeda’s pipeline, completed approximately 150 transactions and invested $1.5 billion in capital in external relationships and investments over a three-year period. In addition, Dr. Curran led the Takeda-CiRA collaboration, a joint research program with Kyoto University’s Center for iPS Cell Research Application.

Prior to his role as Head of CEI, Dr. Curran led the corporate development group at Millennium: The Takeda Oncology Company and was a member of the executive management team. In that role, he oversaw the development and execution of corporate strategic business development initiatives, including licensing arrangements, acquisitions and a range of other transactions.

He has 20 years of pharmaceutical experience in business development, project leadership and development roles. Prior to Millennium, previous professional experiences include a business development role in the Product Planning and Acquisition group at DuPont Merck Pharmaceuticals.

Dr. Curran received an MD from the University of Pennsylvania School of Medicine, an MBA from the Wharton School of the University of Pennsylvania and a BS in chemistry from King’s College.

Dave Grayzel, MD

Observer

Dave Grayzel, MD

Observer

David is a partner at Atlas Venture where he focuses on investments in novel therapeutics, often those that are near to first in human clinical testing. Since joining Atlas in 2010, David has been co-founder and CEO of Arteaus Therapeutics acquired by Eli Lilly, Annovation Biopharma acquired by The Medicines Company, and founding board member of Delinia acquired by Celgene. He was co-founder and currently serves on the boards of Surface Oncology and Cadent, and is a board member at Xilio Therapeutics. David serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the American Heart Association’s One Brave Idea, and the antibody SAB for the Tri-TDI that includes Rockefeller University, MSKCC, and Cornell. He obtained his MD from Harvard Medical School, completed his internal medicine residency at Massachusetts General Hospital, and received his BA from Stanford University.

Press releases

May 21, 2020

Inspired and enabled by the pediatric oncology community, Day One prioritizes promising new medicines that can be rapidly brought to market for children with cancer $60M Series A; Incubated by Canaan; Funded by Access Biotechnology,

Read more...

Resources

May 2019

Timing of first-in-child trials of FDA-approved oncology drugs

Read more...

October 2016

Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents

Read more...

February 2004

The Day One Talk

Read more...

Contact us

Address:

Day One Biopharmaceuticals
395 Oyster Point Blvd., Suite 217
South San Francisco, CA 94080

Telephone:

1-650-484-0899